Determining the income statement and balance sheet as well as distribution of income

The meeting decided to determine the income statement and balance sheet as included in

the presented annual report. The meeting decided to dispose of the company's results

according to the board's proposal in the annual report. Furthermore, it was decided that no

dividend will be paid for the financial year 2021/2022.

Discharge from liability

It was decided to grant the members of the board and the former and current managing

director freedom from liability for the period covered by the annual report presented at the

meeting. The members of the board or the managing director did not participate in this

decision.

Determining the number of board members, board deputies and the number of auditors

as well as determining the fees for the board and the auditors

The meeting decided that the board shall consist of five members without deputies and that

an auditor shall be appointed without deputies. The meeting further decided that directors

remuneration shall amount to a total of no more than SEK 225,000, with the following

distribution: The chairman and CEO shall not receive remuneration, while members who are

not employees of the company shall each receive SEK 75,000. It was decided that the fee to

the auditor should be paid according to an approved bill.

Election of board and auditor

It was decided to appoint Catharina Svanborg, Gabriela Godaly, Carl-Johan Wachtmeister,

Helena Lomberg and Magnus Nylén (new member) as board members for the time until the

end of the next annual general meeting. It was also decided to appoint Catharina Svanborg

as chairman of the board. Furthermore, it was decided to appoint the registered auditing

company Revisorsgruppen i Malmö AB as auditor until the next annual general meeting.

Revisorsgruppen in Malmö AB has announced that they will appoint the auditor Per Ranstam

as chief auditor.

SelectImmune Pharma AB 559104-6874

THE BOARD OF DIRECTORS